Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report.

INTRODUCTION: The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. CASE REPORT: We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. CONCLUSIONS: Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation.